Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prednisone + salbutamol is a combination therapy involving two distinct drugs commonly used in the management of acute asthma and other obstructive airway diseases. Prednisone is a synthetic corticosteroid that acts as an anti-inflammatory and immunosuppressant, reducing airway inflammation and mucus production. Salbutamol (also known as albuterol) is a short-acting, selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle, leading to rapid bronchodilation and relief of bronchospasm. This combination is typically used in hospital or emergency settings for acute asthma exacerbations, where prednisone addresses underlying inflammation while salbutamol provides immediate symptomatic relief by opening airways[1][9][10]. The two drugs are usually administered separately but may be given together as part of an acute treatment protocol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prednisone + salbutamol.